Orchid Revenues Cross $4M Mark, Operating Losses Triple | GenomeWeb

NEW YORK, Nov 9 - Orchid BioSciences reported Thursday third-quarter revenue of $4.9 million, compared with $439,000 in the year ago period as product sales, clinical laboratory testing services, and collaborations and license fees increased sharply.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.